Press Release

NHS England to Provide Innovation and Technology Payment (ITP) to Drive Adoption of HeartFlow Analysis in the United Kingdom

HeartFlow Analysis recognized as proven innovation to deliver efficiency and improve quality in healthcare

REDWOOD CITY, Calif. – April 10, 2018 – HeartFlow, Inc. today announced that NHS England has chosen the HeartFlow FFRCT Analysis as part of the Innovation and Technology Payment (ITP) program. The HeartFlow Analysis was chosen as a new technology to be funded by ITP through a competitive process of nearly 300 applicants. It is the only ITP recipient focused on coronary artery disease (CAD), which affects 2.3 million people in the UK.1

The goal of the ITP is to create the conditions necessary for proven innovations to be adopted faster and more systematically throughout the NHS. Through a competitive process, NHS England identified innovations where financial or procurement barriers were preventing widespread adoption, despite strong evidence that broader adoption would deliver efficiency and improve quality in healthcare. NHS England will provide reimbursement for usage of these technologies through the ITP program to support their adoption throughout the NHS.

“We are delighted that NHS England has chosen to fund and to help encourage widespread adoption of the HeartFlow Analysis as part of the ITP program,” said John H. Stevens, M.D., president and chief executive officer, HeartFlow. “We look forward to working with NHS England to improve efficiency and the patient experience while delivering cost savings as demonstrated in our clinical trials.”

The ITP designation for the HeartFlow Analysis follows medical technology guidance issued by the National Institute for Health and Care Excellence (NICE) in February 2017, which recommended the HeartFlow Analysis as the most cost-effective option following a coronary computed tomography angiogram (CTA) when additional information is needed by the clinician for patients with stable chest pain. Additionally, NICE clinical guidelines recommend coronary CTA as the initial diagnostic test for most patients with stable chest pain.

“For patients being assessed in a chest pain clinic with new onset chest pain, the most important focus is to first provide an accurate diagnosis as quickly as possible. It is ideal if we can avoid unnecessary invasive procedures, like angiograms, or prevent having to do multiple tests, one after the other. Most patients don’t actually have angina and so being able to reassure patients and avoid unnecessary tests is also really important,” said Dr. Andrew Wragg, consultant cardiologist, Barts Heart Centre. “Using the HeartFlow Analysis at the Barts Heart Centre helps us understand if a patient has a significant narrowing within their heart blood vessels by assessing its impact on the actual blood flow to the heart muscle. This enables us to make a more precise diagnosis and offer the most appropriate treatment. Many patients don’t require any extra tests and can be reassured. Other patients can be correctly identified for more invasive treatments. Also, the time to diagnosis is shorter and combined with avoiding unnecessary tests, this can potentially lead to important cost savings for both the hospital and wider healthcare system.”

About the HeartFlow FFRCT Analysis

Clinicians diagnosing someone with suspected CAD want to know as definitively as possible if the individual has a significant blockage in their coronary arteries. They also want to know the impact of that blockage on blood flow so they can best determine which treatment pathway is appropriate (e.g., medical management, stenting or coronary artery bypass grafting).

Data from a patient’s non-invasive coronary CTA are securely uploaded from the hospital’s system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D model of the patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRCT Analysis is provided via a secure online interface to offer actionable information to enable clinicians to determine the optimal course of treatment. To date, clinicians around the world have used the HeartFlow Analysis for more than 15,000 patients to aid in the diagnosis of heart disease.

This technology has been demonstrated to reduce unnecessary and invasive diagnostic coronary angiography procedures, which can be associated with bleeding, stroke, major blood vessel damage and other serious complications. It also significantly reduces healthcare costs for hospitals.2

About HeartFlow, Inc.

HeartFlow, Inc. is a medical technology company redefining the way heart disease is diagnosed and treated. Our non-invasive HeartFlow FFRCT Analysis leverages deep learning to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. Our technology is reflective of our Silicon Valley roots and incorporates decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, Canada, Europe and Japan. For more information, visit www.heartflow.com.


  1. British Heart Foundation. CVD Statistics Factsheet. February 2018. https://www.bhf.org.uk/research/heart-statistics
  2. Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.